Evidence map›Paper›PMID 42427409›Full record

ArticleRSC advances2026

Method development and validation for determination of entinostat in human plasma and its application in breast cancer patients.

Shuo Li, Yuxiang Xu, Jiameng Dong, Yushuo Qiu, Zhixuan Yang, Xiaonan Gao, Jinglin Gao, Zhangying Feng, Caixue Wang, Mingxia Wang

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuo LiDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.ORCID https://orcid.org/0009-0009-7478-0381
Yuxiang XuDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Jiameng DongDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Yushuo QiuDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Zhixuan YangDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Xiaonan GaoDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Jinglin GaoDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Zhangying FengDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Caixue WangDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.
Mingxia WangDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University 12 Jiankang Road Shijiazhuang 050011 People's Republic of China mxia_wang@163.com +86-311-86296233.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Entinostat is an oral histone deacetylase (HDAC) inhibitor used in HR+ breast cancer therapy, for which reliable plasma concentration monitoring is essential for dose optimization and toxicity management. This article described an ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the quantitative analysis of entinostat in human plasma. Samples were concentrated under vacuum after methanol precipitation and separated on a Kinetex C18 column (100 mm × 2.1 mm, 2.6 µm). The mobile phase consisted of acetonitrile and an aqueous solution containing 10 mM ammonium acetate and 0.01% formic acid. The quantitative ion pair for entinostat was

Identifiers

PMID42427409
PMCPMC13347298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.